Lupin says FDA warning letter has no financial impact
This article was originally published in Scrip
Executive Summary
Lupin sees no financial impact on its business as a result of the recent US FDA warning letter that cites certain deficiencies in good manufacturing practice (GMP) at its facility in Mandideep, India.